Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE) have recently come under scrutiny following President Trump’s executive order directing drugmakers to lower medicine prices to match what ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer can cover its dividends with free cash flow, but doesn't have a huge cushion. The company faces some risks from pipeline setbacks, patent expirations, and U.S. government policies.

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for earnings, it missed the same for sales. Earnings of 92 cents per share ...